BIOCONNSEBiocon Limited· PharmaceuticalsMinimalNeutral
Announced Sat, 9 May · 16:18 IST

Biocon Limited has informed the Exchange about Copy of Newspaper Publication for Financial Results

BIOCON · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+6.6%1-day move
₹378.70
prior close
₹380.45
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-2.1-1.0-0.3+0.3+6.6+9.9+10.4+13.7+12.8+14.6+10.0+10.0+9.0
Up moveDown movePending
AI summary

Biocon Limited published newspaper advertisements for its Q4 and FY26 financial results. For Q4 FY26, standalone revenue was Rs 6,047 million and net profit was Rs 510 million. On a consolidated basis, full year revenue stood at Rs 1,69,270 million, with profit before tax of Rs 4,479 million and net profit attributable to shareholders of Rs 3,856 million. Total comprehensive income was Rs 22,993 million. EPS for FY26 was Rs 2.82 (annualized) compared to Rs 8.46 in FY25, representing a significant decline in profitability. The statutory auditors issued unqualified reports.

Likely market impact

The sharp decline in net profit and EPS compared to the previous year may create negative sentiment among investors. The company also announced a postal ballot for key corporate actions including leadership changes and preferential share issuance.